optimizing testing and treatment of patients with brafv600e-mutant mcrc in community practice
Published 2 years ago • 372 plays • Length 52:55Download video MP4
Download video MP3
Similar videos
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
1:04
dr. marshall on the importance of testing for braf mutations in mcrc
-
2:18
prognosticating braf-mutant mcrc
-
26:46
fit to practice? - professor ramesh arasaradnam
-
8:16
encorafenib & binimetinib cetuximab for untreated braf v600e-mutant metastatic colorectal cancer
-
2:11
opti cca-ts2 measure a patient sample
-
18:21
decisional tools to determine need for biopsy and re-biopsy in men with elevated psas
-
56:56
2022 asco follow-up with dr. timothy cannon
-
5:41
final thoughts on optimizing the treatment of mcrc
-
1:13
dr. lenz on breakthrough designation of encorafenib, binimetinib, and cetuximab in braf crc
-
7:15
optimizing biomarker testing for patients with metastatic prostate cancer
-
7:02
triplet regimens in braf-mutant metastatic crc
-
4:41
molecular testing for metastatic crc in 2020
-
3:49
mcrc: combination therapy and testing
-
6:01
beacon trial: triplet therapy in braf v600e–mutated mcrc
-
4:19
targeting braf in metastatic crc
-
4:44
braf testing in colorectal cancer
-
6:18
overcoming acquired resistance mechanisms in braf mcrc
-
6:21
braf and ras mutation status in colorectal cancer
-
13:59
debate 2: braf mutant mcrc patients - clinical trial
-
20:26
role of chemotherapy, treatment sequencing in mcrpc and future directions
-
5:33
treatment options for kras-mutant unresectable mcrc